An Antibody-based Method for Reducing Ocular Inflammation which Can Aid in Corneal Transplantation
HSV keratinitis is characterized, in part, by scarring of the eye as a result of HSV reactivation. To date, corneal transplantation is the standard treatment method. A significant obstacle preventing successful corneal transplantation is inflammation that occurs within the eye (ocular inflammation). Researchers at University of California, Irvine and the University of Oklahoma have identified an antibody that prolongs survival in HSV infected mice and reduces inflammation within the eyes of infected mice. This antibody treatment may offer an attractive method for reducing the severity of ocular inflammation in humans and promoting successful corneal transplantation.
Type of Offer:
« More Biotech Patents« More Pharmaceutical Patents